Your Health, We Care
Release date: 2026-07-17 14:55:14 Recommended: 6
The standard recommended dose is 200 mg orally once daily (or 100 mg based on disease status and initial regimen). For rheumatoid arthritis patients aged ≥65 years or with moderate renal impairment (estimated glomerular filtration rate 30–60 mL/min/1.73m²), dose reduction to 100 mg once daily is recommended. For ulcerative colitis, the drug is contraindicated in patients over 75 years old, and those with renal impairment also require dose reduction. Use is not recommended in severe hepatic impairment (Child-Pugh Class C) due to potentially significantly slowed metabolism. Swallow the tablet whole with a glass of water; do not split, crush, or chew, as this may disrupt the sustained-release properties and affect absorption. It can be taken with or without food, but taking it at the same time each day helps maintain steady-state concentrations. The desiccant (silica gel) inside the bottle should be kept in the bottle to prevent moisture, but must never be ingested. During treatment, your physician will periodically monitor complete blood counts and liver function. If significant leukopenia, anemia, or marked transaminase elevation occurs, dose interruption or permanent discontinuation may be instituted.
If you forget to take your dose at the usual time, take it as soon as you remember; however, if it is less than 12 hours until your next dose (i.e., you missed more than half a day), or if you have missed a full day (24 hours), skip the missed dose and take the next single dose at your scheduled time. Do not take a double dose to make up for a missed one, as this can cause a sudden increase in blood concentrations and increase the risk of adverse effects. If you accidentally ingest more than the prescribed number of tablets, contact your physician or poison control center immediately; monitoring of vital signs and supportive care may be needed. Regarding treatment interruption, do not stop taking the medication without your doctor's approval, as abrupt withdrawal may cause a flare‑up of the underlying disease. If discontinuation is required due to surgery, infection, or planned pregnancy, it should be done under medical guidance with gradual tapering or temporary hold. During the interruption, continue to monitor symptom changes closely. If you decide to permanently stop treatment, be sure to inform your doctor so they can arrange subsequent disease management and alternative therapies.
Adverse reactions to filgotinib are classified by frequency. Common include upper respiratory or nasopharyngeal infections, dizziness, nausea, and laboratory findings of lymphopenia and decreased blood phosphate. Uncommon include vertigo, herpes zoster, pneumonia, sepsis, as well as neutropenia, elevated creatine phosphokinase, and hypercholesterolemia. Although rare, serious infections such as urinary tract infection progressing to pyelonephritis or pneumonia leading to respiratory failure require high vigilance. Persistent high fever, chills, dyspnea, or altered consciousness should be treated as emergencies. Skin reactions such as rash and pruritus are also occasionally reported. Long‑term use warrants attention to cardiovascular events and thrombosis; although incidence is low, consequences can be severe. Any new or worsening symptoms should be proactively reported to your physician or pharmacist. Your doctor will provide individualized guidance based on your specific condition.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
